Grant of Award
OXB
Grant of Award
Oxford, UK – 02 October 2026: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, announces that on 30 September 2026, nil-cost share options over ordinary shares of 50 pence each in the Company were granted under the Company’s 2024 Long Term Incentive Plan ("LTIP") as follows:
Type
Name of individual
Title
Number of share options granted
LTIP - Grant in respect of 2026
Eric Schmidhaeuser
Chief Operating Officer
94,156
LTIP - Grant in respect of 2026: The 2026 LTIP metrics are 60% revenue, 40% Operating EBITDA margin, with target ranges in each case assessed on a constant currency basis which is set out in the Company’s Directors’ Remuneration Report for 2025.
1.
Details of the Issuer or emission allowance market participant
a)
Full name of the entity
Oxford Biomedica plc
b)
LEI code
213800S1GVQNXQ15K851
2.
Reason for the notification
a)
Position/status
Chief Operating Officer
b)
Initial notification / amendment
Initial Notification
3.
Details of the person discharging managerial responsibilities / person closely associated
a)
Is this a PDMR or PCA Submission
Submission for PDMR
b)
Name of natural person
Eric Schmidhaeuser
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Date of the transaction
2026-09-30
b)
Description of instrument
Share
c)
Identification code
ISIN: GB00BDFBVT43
d)
Place of the transaction
Outside the trading venue
e)
Currency
GBP – British Pound
f)
Nature of the transaction
Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards.
g)
Price(s) and volumes(s)
Award
Price
Volume
LTIP grant in respect of 2026
Nil
94,156
h)
Aggregated information
- Aggregated volume
LTIP awards granted over 94,156 shares in total
- Price
Nil
-Ends-
Enquiries:
OXB:
Natalie Walter, Chief Legal Officer and Group Company Secretary - T: +44 (0) 1865 783 000 / E: cosec@oxb.com
ICR Healthcare:
T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com
Mary-Jane Elliott / Sarah Elton-Farr / Philip Marriage
About OXB
OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.
OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDDSHXLLFBQBLZFBB
